

Supplementary Table 1. Baseline characteristics of the study population (n=22)

Demographics and comorbidity	
Age, years, median (IQI)	65.7 (61.9-75.6)
Female sex, n (%)	8 (36.4)
Body mass index, median (IQI)	24.8 (23.8-27.7)
Comorbidities, n (%)	
Cardiovascular disease	11 (50.0)
Diabetes	7 (31.8)
Osteoporosis	5 (22.7)
Myositis characteristics	
Time since diagnosis, years, median (range)	1.2 (0-7.8)
Subtype of IIM, n (%)	
Polymyositis	8 (36.4)
Immune-mediated necrotizing myopathy	5 (22.7)
Dermatomyositis	4 (18.2)
Immune checkpoint inhibitor associated myositis	3 (13.6)
Antisynthetase syndrome	1 (4.5)
Overlap myositis	1 (4.5)
Organ involvement, n (%)	
Myositis	22 (100)
Dysphagia	16 (72.7)
Myocarditis	4 (18.2)
Skin involvement	3 (13.6)
Interstitial lung disease	1 (4.5)
Laboratory results	
ANA-positive (%)	50.0
Polymyositis blood test, n (%)	
Anti-SRP	4 (18.2)
Anti-TIF1	3 (13.6)
Anti-HMG-CoA reductase	2 (9.1)
Anti-PM-Scl (75/100)	2 (9.1)
Anti-Jo1	1 (4.5)
Anti-Ro52	5 (22.7)
Plasma creatine kinase, mean, U/l	1,827.7
Functional test results	
MMT8	
Mean MMT8 ¹ , SD	25.6 (4.1)
Not performed (unable to perform/not tested)	6 (0/6)
6MWT	
Mean 6MWT ² (meters), SD	341.8 (146.6)
Not performed (unable to perform/not tested)	15 (8/7)
Grip strength	
Mean grip strength (kg) ³ , SD	58.2 (25.7)
Not performed (unable to perform/not tested)	7 (0/7)
IVIG	
Indications for IVIG treatment	
Insufficient effect of prior immunosuppressive medication	18 (81.8)
Dysphagia	5 (22.7)
Others ⁴	3 (13.6)

Treatment effects of IVIG for inflammatory myositis

Corticosteroids	
Prednisolone dose, mean, mg/day	44.7
Pulse corticosteroid therapy, n (%)	4 (18.2)
Other immunosuppressive treatment	
DMARD treatment at baseline, n (%)	14 (63.6)
Most frequent DMARD treatment at baseline, n (%)	
Methotrexate	6 (27.3)
Azathioprine	5 (22.7)
Rituximab	5 (22.7)
Mycophenolate mofetil	2 (9.1)
Cyclophosphamide	1 (4.6)
Previous DMARD treatment, n (%)	14 (63.6)
Previous treatment with three or more immunosuppressants, n (%)	6 (27.3)
Most frequent previous DMARD treatment, n (%)	
Azathioprine	11 (36.4)
Methotrexate	9 (31.8)
Rituximab	9 (27.3)
Mycophenolate mofetil	3 (13.6)

Abbreviations: ANA, antinuclear antibodies; anti-HMGCR, anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase antibodies; anti-Jo-1, anti-Histidyl tRNA Synthetase antibodies; anti-PM-Scl, anti-Polymyositis-Scleroderma antibodies; anti-Ro52, anti-Ro52 antibodies; anti-SRP, anti-Signal Recognition Particle antibodies; anti-TIF1, anti-Transcription Intermediary Factor 1 antibodies; IIM, idiopathic inflammatory myopathy; DMARD, Disease-Modifying Antirheumatic Drug; IVIG, intravenous immunoglobulin; MMT8, Manual Muscle Test 8; 6MWT, 6-minute walk test.

¹Manual Muscle Test 8 of 16 patients included. (The maximum sum was 40)

²6-Minute Walk Test of 7 patients included

³Grip strength of 15 patients included

⁴The "Others" category included: decreasing functional capacity, relative contraindications for corticosteroids, and testing for reversible inflammatory disease vs. Sporadic Inclusion Body Myositis
